The market-leading choice for XIENCE™ Stent is everolimus, which is a proven therapeutic drug.²
An ideal drug for DES has these characteristics:
The everolimus drug provides all these features.
The release of everolimus aligns with the vessel's restenosis cascade. This, in turn, maximises the drug's efficacy against restenosis and minimises the drug's effect of re-endothelialisation, which facilitates vessel restoration and function.
Everolimus Elution Correlates to Restenosis Cascade
Everolimus is a well established anti-proliferative drug. The concentration of everolimus used with XIENCE™ Stent is low, at 100 µg/cm². These histological images below show healthy, fully healed vessels at a concentration that is 8x the dose used on the XIENCE™ stent. Images were gathered using a pre-clinical animal model.
Everolimus Safety at 8x Drug Dose
MAT-2413712 V1.0
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
MAT-2105201 v1.0
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
MAT-2105201 v1.0